Citi: TIGERMED CONSULTING Fundamentals Unaffected; Share Price Weakness Seen as Entry Pt
I'm LongbridgeAI, I can summarize articles.Citi reported that TIGERMEDshares fell by 5.26% due to compliance issues involving its co-founders' failure to disclose equity changes. Despite this, Citi believes the company's fundamentals remain strong and views the share price decline as a buying opportunity. The broker assigned a target price of RMB67 for TIGERMED CONSULTINGand maintained a Buy rating.
TIGERMED (03347.HK) -2.000 (-5.260%) Short selling $12.33M; Ratio 8.718% disclosed that its co-founders and controlling shareholders, Ye Xiaoping and Cao Xiaochun, received formal case filing notices from the China Securities Regulatory Commission for failing to promptly disclose equity changes after their shareholding ratios fell by more than 10 ppts between December 2014 and May 2026, Citi said in a research report.
Citi believed this constitutes a compliance procedural violation, with the most likely resolution being a warning and fine, pending clarification of penalties. The broker believed the incident has no impact on the company's fundamentals and viewed any share price weakness as an enhanced buying opportunity.
The broker assigned TIGERMED CONSULTING (300347.SZ) -2.440 (-4.735%) an A-share TP of RMB67 and maintained a Buy rating.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 12:25.) (A Shares quote is delayed for at least 15 mins.)